Trial Condition(s):
BAY94-8862, Age and Gender Study
14508
Not Available
Not Available
Primary objective: To investigate the influence of age and gender on the pharmacokinetics of BAY 94-8862 given as a 10 mg immediate-release tablet single dose in young and elderly healthy male and female subjects (of non-childbearing potential)
Secondary objectives: To assess safety and tolerability of BAY 94-8862
- Healthy subjects were assigned to 1 of 4 age and gender groups ie young men aged 18 – 45 years, elderly male subjects aged 65 – 80 years (was to include approximately 4 – 6 subjects aged ≥73 years) as well as young and elderly women (same age limits as for men).
- Clinically relevant changes/deviations from normal ECG, clinical examination, clinical chemistry, hematology, urinalysis, and/or blood pressure, heart rate (vital signs), or physical examination - Regular use of therapeutic or recreational drugs - Positive testing in drug screening and or alcohol breath test - Recent donation of blood/blood components - Subjects hypersensitive to the investigational drugs, their components and/or with a history of multiple drug allergies, non-allergic drug reactions, or severe allergies - History of / current relevant diseases of vital organs or of the central nervous system and/or medical conditions/disorder/illness that would impair subject’s ability to participate in the trial or that may affect study results, diagnosed malignancy, psychiatric disorders - Regular daily consumption of an amount of beer, alcohol, xanthine-containing beverages, and/or cigarettes that may affect study results - Intake of foods or beverages containing grapefruit within 2 weeks before study drug administration - Regular use of medicines and use of medication within the 2 weeks preceding the study, especially strong CYP3A4 inducers, weak to moderate CYP3A4 inhibitors and strong inhibitors of CYP3A4 or strong inhibitors of CYP2C8 - Excluded therapies (eg physiotherapy, acupuncture, etc) - Clinically relevant findings in the physical examination - Positive results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibodies (anti-HCV), human immune deficiency virus antibodies (anti-HIV 1+2) (under Laboratory examinations) - Serum potassium level greater than equal to 5.0 mmol/L or serum sodium level less than equal to130 mmol/L - Subjects should not take any concomitant chronic medication, except aspirin for cardioprotection; thyroid hormone replacement, provided the serum T3, T4 and TSH values are normal at Screening; topical anti-glaucoma medications; topical medications including artificial tears, dry skin creams and topical steroid preparations; low dose estrogen for hormone replacement. Vitamins or multivitamins with or without calcium and/or iron may be taken up to Day -1 and may be resumed on Day 4
Locations | |
---|---|
Locations Investigative Site Köln, Germany, 51063 | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Study to investigate the influence of age and gender on the pharmacokinetics of a single oral dose of a 10 mg BAY 94-8862 IR tablet in a randomized, single-blind, placebo-controlled, group-comparison design in healthy male and female subjects
Trial Type:
Interventional
Intervention Type:
Drug
Trial Purpose:
Other
Allocation:
Randomized
Blinding:
Single Blind
Assignment:
Parallel Assignment
Trial Arms:
5
Not Available